Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $232 from $225 and keeps an Overweight rating on the shares. Tenet delivered “another strong earnings report” and higher margins and improving free cash flow are supporting capital investment to add higher acuity service lines in the hospital segment and exceed targeted M&A in Ambulatory Surgical Centers, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $238 from $221 at Guggenheim
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare price target raised to $230 from $225 at BofA
- Morning Movers: UPS and PayPal jump following quarterly reports